July 5th, 2016, Vancouver, B.C. – Veritas Pharma Inc. (“VRT” or the “Company”) (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), an early stage pharmaceutical company developing innovative medicinal cannabis cultivars for specific disease conditions such as chronic pain, emesis (nausea/vomiting), and epilepsy, today announced that Mr. Matthew Hamilton joined its Board of Directors as an independent director, effective immediately. Matthew will be replacing Mr. Jason Birmingham who is stepping down as director as of today to focus on other current roles that have become increasingly active over the last several months. Mr. Birmingham will retain an advisory role with the Company.

Mr. Matthew Hamilton is an international entrepreneur with over ten years of public market experience primarily in executive, investment banking and investor relation’s capacities. He has been active as an executive and director in several public companies from 2008-2013 and more recently he was a founder of Tundra Copper Inc., that was acquired by Kaizen Discovery in 2015. Matthew holds undergraduate and graduate degrees specializing in management and finance from the University of British Columbia.

“We are pleased to welcome Mr. Hamilton to the Board of Directors”, commented Veritas CEO Dr. Lui Franciosi. “Mr. Hamilton brings in an understanding of public markets, compliance and investor relations. We are confident he will provide our Board with much expertise that would have been otherwise lost with Mr. Birmingham’s departure.”

About VERITAS Pharma Inc.

Veritas Pharma Inc. is an early stage pharmaceutical company developing innovative medicinal cannabis cultivars for specific disease conditions such as chronic pain, emesis (nausea/vomiting), and epilepsy. Using a ‘lean and mean’ approach to product development, the company aims to select candidate cultivars using classical pharmacology techniques and then immediately evaluate them in the clinic to maximize both product value and shareholder return. Veritas’s scientists are an inter-disciplinary team that consists of chemists, pharmacologists, anesthetists, and clinical pharmacologists. Their focus is to use their knowledge to streamline the development of cannabis based treatments to capture considerable market share.

On behalf of the Board of Directors Veritas Pharma Inc.

“Dr. Lui Franciosi”
Dr. Lui Franciosi
Chief Executive Officer

Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com.

Investor and Public Relations Contact

Veritas Pharma Inc. Sam Eskandari

Telephone: +1.416.918.6785
Email: [email protected] Website: www.veritaspharmainc.com

The CSE has not reviewed, nor approved or disapproved the content of this press release.

The Veritas Newsletter

Enter your email to receive news alerts and updates from Veritas Pharma.

You have Successfully Subscribed!